Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with schizophrenia or schizoaffective disorder, for at least 1 year before screening~* Clinically stable with no hospitalizations for schizophrenia exacerbation or change in current antipsychotic medications for 3 months prior to screening~* Stabilized on antipsychotic medications other than risperidone, paliperidone, ziprasidone, clozapine, thioridazine, or any long acting injectable.~* For panel D only, no detectable plasma concentration of risperidone or paliperidone \> 0.1ng/mL at screening. A quantifiable and stable level of paliperidone not exceeding 0.25 ng/mL is allowed if such paliperidone value is explained by (documented) use of paliperidone palmitate (last dose administered \> 12 months prior to baseline)~* Has a total PANSS score of 70 or less at both screening and Day-1 (Period 1)~* Woman is postmenopausal, surgically sterile, abstinent or, if sexually active, practices an effective method of birth control during participation in the study or for at least 6 months after the last dose of study drug, whichever is longer~* Woman has negative pregnancy test at screening and on Day -1 of Period 1~* Man agrees to use an adequate contraception method as deemed appropriate by the investigator and agrees to not donate sperm during participation in the study or for at least 6 months after the last dose of study drug, whichever is longer~* Body Mass Index (BMI) between 17 and 35 kg/m2 (inclusive). Body weight of at least 50 kg for patients enrolled in panel A, B and C. For patients enrolled in panel D only: body weight of at least 47 kg~Exclusion Criteria:~* Attempted suicide within 12 months before screening or is at imminent risk of suicide or violent behavior~* Has diagnosis of alcohol or substance dependence, with the exception of nicotine or caffeine dependence, within 12 months prior to screening, or diagnosis of substance abuse within 3 months prior to screening~* Has a positive drug screen test for barbiturates, cocaine, amphetamines or opiates, or has a positive alcohol screen test unless positive toxicology screen is explained by a prescribed allowed medication~* Is in his/her first episode of psychosis~* Has a history of or has a current clinically significant medical illness that the investigator considers should exclude the patients or that could interfere with the interpretation of the study results~* Has clinically significant abnormal values at screening or at baseline for hematology, clinical chemistry or for urinalysis, as deemed appropriate by the investigator~* Has a clinically relevant abnormality in the physical examination, vital signs or 12 lead electrocardiogram (ECG) at screening or at baseline as deemed appropriate by the investigator~* Has a history or presence of circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval~* Concomitant use of medications that the investigator considers should exclude the patients or that could interfere with the interpretation of the study results~* Any other condition or circumstance that the investigator considers should exclude the patients or that could interfere with the interpretation of the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Panel A (Type: EXPERIMENTAL): Panel A consists of 2 treatment groups
- Panel B (Type: EXPERIMENTAL): Panel B consists of 5 treatment groups
- Panel C (Type: EXPERIMENTAL): Panel C consists of 1 treatment group
- Panel D (Type: EXPERIMENTAL): Panel D consists of 4 treatment groups

Based on this trial design, predict the completion outcome and termination type (if applicable).